<DOC>
	<DOCNO>NCT00427076</DOCNO>
	<brief_summary>Methicillin-resistant Staphylococcus aureus ( SA ) major pathogen cause mainly health-care associated infection , lately , also community acquire infection . Few treatment choice exist treat infection . The currently recommend antibiotic infection glycopeptides ( vancomycin teicoplanin ) . Glycopeptide treatment hs several disadvantage . It last resort antibiotic family reserve future ; Vancomycin less effective beta-lactam drug SA infection susceptible agent ; treatment give intravenously ; use vancomycin lead development SA strain partial complete resistance vancomycin . Cotrimoxazole old antibiotic active strain MRSA , depend local epidemiology . Study hypothesis : The purpose study show cotrimoxazole effective treatment vancomycin invasive MRSA infection . We plan randomize controlled trial compare treatment cotrimoxazole vs. vancomycin invasive MRSA infection . The primary efficacy outcome ass Improvement cure without antibiotic modification , define : survival 7 day post randomization resolution fever ( &lt; 38 two consecutive day ) resolution hypotension ( &gt; 90 systolic without need vasopressor support ) ; physician 's assessment primary infection improve cure . The primary safety outcome all-cause 30-day survival .</brief_summary>
	<brief_title>Cotrimoxazole Versus Vancomycin Invasive Methicillin-resistant Staphylococcus Aureus Infections</brief_title>
	<detailed_description>Staphylococcus aureus ( SA ) major pathogen cause community-acquired health-care associate infection . In hospital , SA infection associate significant burden ; in-hospital mortality last 15 year follow SA bacteremia Beilinson hospital 38 % decrease recent year . Resistance beta-lactams widely prevalent hospital ( 57 % SA isolate cause bacteremia center ) . The drug choice currently recommend infection glycopeptide ( vancomycin teicoplanin ) . Cotrimoxazole ( trimethoprim-sulfamethoxazole ) relatively 'old ' drug commonly use urinary tract infection . Invitro , active SA , include methicillin-resistance Staphylococcus aureus ( MRSA ) strain activity SA bactericidal . Trimethoprim alone bactericidal SA , sulphamethoxazole alone relatively inactive combination synergistic in-vitro invivo . The prevalence cotrimoxazole-susceptible SA varies locally . At center , 97 % SA strain cause bacteremia 2004 susceptible cotrimoxazole . Community-acquired MRSA , prevalent United States cause severe skin soft tissue infection , describe Israel . Several reason exist search antibiotic vancomycin MRSA infection . Vancomycin less effective beta-lactam drug SA infection susceptible agent . It last resort antibiotic MRSA infection currently recommend bactericidal antibiotic invasive infection . Use vancomycin lead development SA strain partial complete resistance vancomycin ( VISA VRSA , respectively ) . Vancomycin use associate appearance vancomycin-resistant enterococcus ( VRE ) specie . Nosocomial infection VISA VRE difficult treat may spread rapidly hospital . 10 Finally , vancomycin administer orally . Limited evidence support efficacy cotrimoxazole MRSA infection , paucity data high-burden invasive infection . Cotrimoxazole probably inferior vancomycin methicillin-susceptible SA . ; thus may infer indirectly inferiority methicillin drug alike MRSA infection . Cotrimoxazole may less effective glycopeptides oxacillin left-sided endocarditis . No evidence exist support use cotrimoxazole empirically treatment suspect SA infection hospital . We plan open label single-center pragmatic randomize controlled trial compare cotrimoxazole vancomycin . We include patient document highly suspect MRSA infection , accord pre-defined risk factor . We choose target patient population ass efficacy cotrimoxazole empirically documented infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Adults &gt; 18 year provide sign informed consent , unable , legal guardian caretaker sign inform consent Patients document MRSA infection : MRSA bacteremia Other microbiologically document MRSA infection define clinical source infection ( CDC criterion ) plus microbiological documentation MRSA source infection Patients highly probable MRSA infection , prior microbiological documentation pathogen : Suspected neurosurgical meningitis ( include VPshunt meningitis ) Sepsis hemodialysis Ventilatorassociated pneumonia prior antibiotic treatment within 48 hour Catheterrelated suspect catheterrelated infection Surgical site infection presence foreign body Exclusion randomization : Previous antibiotic treatment direct MRSA &gt; 48 hour ( include vancomycin , fucidic acid , rifampicin cotrimoxazole ) Known allergy either study drug Acute leukemia and/ BMT neutropenia &lt; 500/mm3 &lt; 1000/mm3 expect decrease 500/mm3 Pregnancy , lactation Previous enrollment study Concurrent participation another trial Exclusions randomization : Documented Staphylococcal infection resistant cotrimoxazole VISA VRSA Documented MSSA Documented leftsided endocarditis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>vancomycin</keyword>
	<keyword>cotrimoxazole</keyword>
	<keyword>trimethoprim/ sulfamethoxazole</keyword>
	<keyword>methicillin-resistant Staphylococcus aureus</keyword>
	<keyword>Health care association infection</keyword>
	<keyword>MRSA bacteremia microbiologically document MRSA infection ( define clinically CDC criterion )</keyword>
	<keyword>Suspected neurosurgical meningitis</keyword>
	<keyword>Sepsis hemodialysis , catheter-associated catheter-related infection</keyword>
	<keyword>Ventilator-associated pneumonia</keyword>
	<keyword>Surgical site infection presence foreign body</keyword>
</DOC>